Pascal Biosciences Inc
XTSX:PAS

Watchlist Manager
Pascal Biosciences Inc Logo
Pascal Biosciences Inc
XTSX:PAS
Watchlist
Price: 0.015 CAD -25% Market Closed
Market Cap: 983.9k CAD

Profitability Summary

Pascal Biosciences Inc's profitability score is 60/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

60/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

60/100
Profitability
Score
60/100
Profitability
Score

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Pascal Biosciences Inc

Revenue
0 CAD
Operating Expenses
-431.3k CAD
Operating Income
-431.3k CAD
Other Expenses
-49k CAD
Net Income
-480.3k CAD

Margins Comparison
Pascal Biosciences Inc Competitors

Country Company Market Cap Operating
Margin
Net
Margin
CA
Pascal Biosciences Inc
XTSX:PAS
983.9k CAD N/A N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
-21 040%
US
Abbvie Inc
NYSE:ABBV
398.1B USD
33%
4%
US
Amgen Inc
NASDAQ:AMGN
174.6B USD
34%
19%
US
Gilead Sciences Inc
NASDAQ:GILD
151.1B USD
39%
28%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.8B USD
39%
31%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
-392%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
28%
32%
AU
CSL Ltd
ASX:CSL
84.2B AUD
26%
19%
NL
argenx SE
XBRU:ARGX
45B EUR
22%
43%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.4B USD
8%
1%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Pascal Biosciences Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CA
Pascal Biosciences Inc
XTSX:PAS
983.9k CAD
51%
-2 552%
52%
70%
FR
Pharnext SCA
OTC:PNEXF
6T USD
115%
-391%
275%
3 093%
US
Abbvie Inc
NYSE:ABBV
398.1B USD
139%
2%
20%
28%
US
Amgen Inc
NASDAQ:AMGN
174.6B USD
82%
8%
17%
15%
US
Gilead Sciences Inc
NASDAQ:GILD
151.1B USD
41%
14%
25%
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.8B USD
22%
16%
23%
25%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
15%
12%
11%
12%
AU
CSL Ltd
ASX:CSL
84.2B AUD
16%
8%
12%
10%
NL
argenx SE
XBRU:ARGX
45B EUR
30%
26%
15%
62%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.4B USD
33%
1%
8%
-21%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less